JP2012067110A5 - - Google Patents

Download PDF

Info

Publication number
JP2012067110A5
JP2012067110A5 JP2011233850A JP2011233850A JP2012067110A5 JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5 JP 2011233850 A JP2011233850 A JP 2011233850A JP 2011233850 A JP2011233850 A JP 2011233850A JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5
Authority
JP
Japan
Prior art keywords
use according
chlorite
disorder
tcdo
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011233850A
Other languages
English (en)
Japanese (ja)
Other versions
JP5797083B2 (ja
JP2012067110A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012067110A publication Critical patent/JP2012067110A/ja
Publication of JP2012067110A5 publication Critical patent/JP2012067110A5/ja
Application granted granted Critical
Publication of JP5797083B2 publication Critical patent/JP5797083B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011233850A 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸 Expired - Lifetime JP5797083B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006552151A Division JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015118841A Division JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Publications (3)

Publication Number Publication Date
JP2012067110A JP2012067110A (ja) 2012-04-05
JP2012067110A5 true JP2012067110A5 (enExample) 2013-04-04
JP5797083B2 JP5797083B2 (ja) 2015-10-21

Family

ID=34860199

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸
JP2011233850A Expired - Lifetime JP5797083B2 (ja) 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Country Status (7)

Country Link
US (5) US7105183B2 (enExample)
EP (2) EP2574342B1 (enExample)
JP (3) JP5072367B2 (enExample)
CN (2) CN102423318B (enExample)
AU (1) AU2005213300B2 (enExample)
CA (2) CA2554511C (enExample)
WO (1) WO2005076819A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273888B2 (en) * 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US20090215196A1 (en) * 2004-07-16 2009-08-27 Gyros Patent Ab Sequential Method
ES2820430T3 (es) 2005-05-09 2021-04-21 Labrador Diagnostics Llc Sistemas de fluidos para centros de atención y usos de los mismos
CN101253409A (zh) * 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
EP1979269A4 (en) * 2005-12-22 2013-01-02 Taiji Biomedical Inc CHLORINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) * 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ES2374845T3 (es) * 2006-05-22 2012-02-22 Xbiotech, Inc Tratamiento de cáncer con anticuerpos anti-il-1.
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
NZ590033A (en) * 2008-05-30 2011-08-26 Xbiotech Inc Interleukin-1alpha antibodies and methods of use
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
AU2010281524A1 (en) 2009-08-06 2012-02-23 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders
CA2778270C (en) 2009-10-19 2021-01-05 Theranos, Inc. Integrated health data capture and analysis system
JP5904953B2 (ja) * 2010-03-10 2016-04-20 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
WO2012024161A1 (en) * 2010-08-16 2012-02-23 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
RU2013110030A (ru) 2010-08-23 2014-09-27 ИксБиотеч, Инк. Лечение неопластических заболеваний
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
MX2014007664A (es) 2011-12-22 2015-05-11 Nuvo Res Gmbh Composiciones liposomicas de clorito o clorato.
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US20170106017A1 (en) * 2014-05-16 2017-04-20 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
GB2626503A (en) 2021-10-04 2024-07-24 Neuvivo Inc Treatment methods for ALS patients
CA3253808A1 (en) * 2022-05-19 2023-11-23 Neuvivo, Inc. BIOMARKERS OF NEURODEGENERATIVE DISEASES
US20250114396A1 (en) * 2023-07-07 2025-04-10 The Regents Of The University Of California Chlorite uses for stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (de) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (de) 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
ATE258799T1 (de) * 1997-10-06 2004-02-15 Oxo Chemie Ag Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (ja) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center マクロファージ機能調節剤
CA2393136A1 (en) * 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Similar Documents

Publication Publication Date Title
JP2012067110A5 (enExample)
JP2012092110A5 (enExample)
JP2014515013A5 (enExample)
JP2014521659A5 (enExample)
JP2015525757A5 (enExample)
JP2013509429A5 (enExample)
JP2013014622A5 (enExample)
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
JP2014515737A5 (enExample)
JP2014507446A5 (enExample)
JP2014507482A5 (enExample)
JP2012107014A5 (enExample)
BR112014000268A2 (pt) pirazolopiridinas com substituinte heteroarilo e utilização destas
AR094202A1 (es) Productos para el cuidado oral que contienen un complejo de zinc tetrabasico-acido amino-haluro, metodo
JP2011102304A5 (enExample)
JP2013520405A5 (enExample)
JP2012193216A5 (enExample)
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
JP2014530840A5 (enExample)
JP2013507408A5 (enExample)
EA201792071A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112015025675A2 (pt) derivados do tipo bisamida de ácido dicarboxílico, uso dos mesmos, composição farmacêutica à base dos mesmos, e métodos para produzir derivados do tipo bisamida de ácido dicarboxílico
JP2017002035A5 (enExample)
JP2015516419A5 (enExample)